AstraZeneca (NASDAQ:AZN) Given New £120 Price Target at Barclays

AstraZeneca (NASDAQ:AZNGet Rating) had its price target boosted by Barclays from £115 ($149.86) to £120 ($156.37) in a research report released on Thursday morning, The Fly reports.

AZN has been the topic of a number of other reports. Credit Suisse Group raised their price target on shares of AstraZeneca from GBX 9,000 ($117.28) to £110 ($143.34) in a research report on Friday, April 8th. SVB Leerink lifted their price objective on shares of AstraZeneca from $65.00 to $70.00 and gave the company an outperform rating in a research report on Thursday, February 24th. Stifel Nicolaus initiated coverage on shares of AstraZeneca in a research note on Monday, February 28th. They set a buy rating on the stock. JPMorgan Chase & Co. raised their target price on shares of AstraZeneca from £100 ($130.31) to £120 ($156.37) in a research note on Thursday, April 7th. Finally, TheStreet raised shares of AstraZeneca from a c+ rating to a b- rating in a research note on Thursday, March 10th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of Buy and a consensus target price of $6,669.29.

AZN opened at $69.05 on Thursday. The company has a fifty day simple moving average of $62.69 and a 200 day simple moving average of $60.04. The firm has a market cap of $213.97 billion, a price-to-earnings ratio of 493.25, a PEG ratio of 1.30 and a beta of 0.48. AstraZeneca has a twelve month low of $50.60 and a twelve month high of $71.70. The company has a current ratio of 1.16, a quick ratio of 0.76 and a debt-to-equity ratio of 0.72.

AstraZeneca (NASDAQ:AZNGet Rating) last released its quarterly earnings results on Thursday, February 10th. The company reported $0.84 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.77 by $0.07. The business had revenue of $11.50 billion during the quarter, compared to analyst estimates of $11.06 billion. AstraZeneca had a net margin of 0.30% and a return on equity of 27.48%. The business’s revenue was up 55.2% on a year-over-year basis. During the same period last year, the business earned $0.54 EPS. On average, analysts forecast that AstraZeneca will post 3.31 earnings per share for the current fiscal year.

The company also recently announced a semi-annual dividend, which was paid on Monday, March 28th. Stockholders of record on Friday, February 25th were paid a $0.985 dividend. This represents a dividend yield of 2.4%. The ex-dividend date was Thursday, February 24th. This is an increase from AstraZeneca’s previous semi-annual dividend of $0.45. AstraZeneca’s payout ratio is currently 1,378.67%.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. RB Capital Management LLC boosted its stake in shares of AstraZeneca by 1.8% during the first quarter. RB Capital Management LLC now owns 8,381 shares of the company’s stock valued at $556,000 after purchasing an additional 151 shares in the last quarter. Pinnacle Bancorp Inc. boosted its stake in shares of AstraZeneca by 13.4% during the first quarter. Pinnacle Bancorp Inc. now owns 1,317 shares of the company’s stock valued at $87,000 after purchasing an additional 156 shares in the last quarter. Kingsview Wealth Management LLC boosted its stake in shares of AstraZeneca by 2.5% during the third quarter. Kingsview Wealth Management LLC now owns 7,168 shares of the company’s stock valued at $431,000 after purchasing an additional 176 shares in the last quarter. BerganKDV Wealth Management LLC boosted its stake in shares of AstraZeneca by 27.4% during the third quarter. BerganKDV Wealth Management LLC now owns 842 shares of the company’s stock valued at $51,000 after purchasing an additional 181 shares in the last quarter. Finally, Regal Investment Advisors LLC boosted its stake in shares of AstraZeneca by 4.8% during the fourth quarter. Regal Investment Advisors LLC now owns 4,038 shares of the company’s stock valued at $235,000 after purchasing an additional 185 shares in the last quarter. Institutional investors and hedge funds own 20.54% of the company’s stock.

AstraZeneca Company Profile (Get Rating)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Featured Stories

The Fly logo

Analyst Recommendations for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.